FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2625132009> ?p ?o ?g. }

• W2625132009 abstract "The neurodegenerative autoimmune disease multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). When myelin sheaths of the nerve axons are offended, multiple demyelinating lesions develop. MS-patients constitute approx. 8% of the whole neurologically treatment. The aim of the current immunmodulatory therapies is to prevent new axonale defects and to inhibit the deterioration of the existing neurological deficits. This is also the case with Betaferon® (Interferon beta- 1b). Because of the subcutaneous injections and flu-like side effects, the therapy can be a great challenge for the patients. A lack of adherence is no rarity. Since 2001 the patient compliance program BETAPLUS® exists to care and support patients with their Betaferon® therapy. In the following study, the patient compliance program BETAPLUS® with the entire 8141 participants were tested with regard to: quality of life, side effects and compliance. The information was derived from the database “PCP”. After every telephone contact, these categories were assigned to the gradations “red”, “yellow” and “green”. Furthermore, the patients who broke off therapy in the period of 2004-2010 were analysed concerning their reasons. The evaluation of the flu-like side effects showed a “green” result of 63, 54%. For this group of patients, the flu-like syndrome has no negative impact. 8,51% had some minor problems (“yellow”), 2,96% (“red”) are strongly affected by the flu-like syndrome. Another side effect is the dermal injection side reaction. 57, 51% of the patients had a “green” value and thus no negative effect. 71, 64% showed a “green” compliance. In merely 0, 11% of all cases, a “red” value and therefore an insufficient compliance could be detected. On average, every patient has telephone contact with the BETAPLUS® Serviceteam five times a year. The analysis of the dropout reasons displays the following percentage distribution: flu-like syndrome (22, 39%), no effect (15, 16%), change of the medication (9, 24%), further development of the disease (6, 79%) and dermal injection side reaction (6, 64%). On average, the dropout patients were 46 months on therapy and therefrom 23 months a participant of the BETAPLUS® program. These results show the positive effect of patient compliance programs with regard to the continuation of the therapy and coping with chronical illness. The high response rate and the great number of contacts with the serviceteam express the need for advice and care concerning the ms-patients and the program is a measure in order to improve patient-oriented care." @default.
• W2625132009 created "2017-06-23" @default.
• W2625132009 creator A5084206607 @default.
• W2625132009 date "2022-02-20" @default.
• W2625132009 modified "2023-10-14" @default.
• W2625132009 title "Evaluation des Patientenbetreuungsprogramms BETAPLUS® zur begleitenden Unterstützung der Therapie mit Betaferon® (Interferon beta-1b)" @default.
• W2625132009 doi "https://doi.org/10.53846/goediss-1594" @default.
• W2625132009 hasPublicationYear "2022" @default.
• W2625132009 type Work @default.
• W2625132009 sameAs 2625132009 @default.
• W2625132009 citedByCount "0" @default.
• W2625132009 crossrefType "dissertation" @default.
• W2625132009 hasAuthorship W2625132009A5084206607 @default.
• W2625132009 hasBestOaLocation W26251320091 @default.
• W2625132009 hasConcept C126322002 @default.
• W2625132009 hasConcept C187212893 @default.
• W2625132009 hasConcept C199360897 @default.
• W2625132009 hasConcept C203014093 @default.
• W2625132009 hasConcept C2779134260 @default.
• W2625132009 hasConcept C2780640218 @default.
• W2625132009 hasConcept C2994247566 @default.
• W2625132009 hasConcept C3454156 @default.
• W2625132009 hasConcept C41008148 @default.
• W2625132009 hasConcept C71924100 @default.
• W2625132009 hasConceptScore W2625132009C126322002 @default.
• W2625132009 hasConceptScore W2625132009C187212893 @default.
• W2625132009 hasConceptScore W2625132009C199360897 @default.
• W2625132009 hasConceptScore W2625132009C203014093 @default.
• W2625132009 hasConceptScore W2625132009C2779134260 @default.
• W2625132009 hasConceptScore W2625132009C2780640218 @default.
• W2625132009 hasConceptScore W2625132009C2994247566 @default.
• W2625132009 hasConceptScore W2625132009C3454156 @default.
• W2625132009 hasConceptScore W2625132009C41008148 @default.
• W2625132009 hasConceptScore W2625132009C71924100 @default.
• W2625132009 hasLocation W26251320091 @default.
• W2625132009 hasOpenAccess W2625132009 @default.
• W2625132009 hasPrimaryLocation W26251320091 @default.
• W2625132009 hasRelatedWork W2035673585 @default.
• W2625132009 hasRelatedWork W2412026061 @default.
• W2625132009 hasRelatedWork W249021389 @default.
• W2625132009 hasRelatedWork W2503374361 @default.
• W2625132009 hasRelatedWork W2617222556 @default.
• W2625132009 hasRelatedWork W2883833415 @default.
• W2625132009 hasRelatedWork W4249488207 @default.
• W2625132009 hasRelatedWork W4255340848 @default.
• W2625132009 hasRelatedWork W4298870441 @default.
• W2625132009 hasRelatedWork W2186187480 @default.
• W2625132009 isParatext "false" @default.
• W2625132009 isRetracted "false" @default.
• W2625132009 magId "2625132009" @default.
• W2625132009 workType "dissertation" @default.